A5059063118- Renal cell carcinoma treatment
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Testicular diseases and treatments
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Ferroptosis and cancer prognosis
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Ovarian cancer diagnosis and treatment
- Urologic and reproductive health conditions
- Epigenetics and DNA Methylation
- Cancer Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Cancer therapeutics and mechanisms
- CAR-T cell therapy research
- Sexual Differentiation and Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Microscopic Colitis
- Clostridium difficile and Clostridium perfringens research
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2016-2025
Kettering University
2015-2024
Cleveland Clinic
1999-2023
Texas Oncology
2006-2023
Seattle Cancer Care Alliance
2009-2023
City of Hope
2007-2023
New York Proton Center
2010-2019
Accreditation Council for Graduate Medical Education
2019
Memorial Hospital
1991-2019
Since sunitinib malate has shown activity in two uncontrolled studies patients with metastatic renal-cell carcinoma, a comparison of the drug interferon alfa phase 3 trial is warranted.We enrolled 750 previously untreated, carcinoma multicenter, randomized, to receive either repeated 6-week cycles (at dose 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) or 9 MU subcutaneously three times weekly). The primary end point was progression-free survival. Secondary...
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab everolimus carcinoma who had received previous treatment.
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma a pilot study. This phase 3 trial compared nivolumab sunitinib for previously untreated clear-cell carcinoma.
Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target rapamycin kinase, may benefit patients with this disease.In multicenter, phase 3 trial, we randomly assigned 626 previously untreated, poor-prognosis to receive 25 mg intravenous temsirolimus weekly, million U interferon (with an increase 18 U) subcutaneously three times or combination therapy 15 weekly plus 6 weekly. The...
In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses patients with advanced renal-cell carcinoma. This 3 trial involving previously untreated carcinoma compared the standard-of-care sunitinib.
A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final analyses and updated results are reported.
Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients metastatic renal-cell carcinoma. This 3, randomized trial the efficacy safety of pazopanib first-line therapy. We randomly assigned 1110 clear-cell, carcinoma, 1:1 ratio, to receive continuous dose (800 mg once daily; 557 patients) 6-week cycles (50 daily for 4 weeks, followed by 2 weeks without treatment; 553 patients). The primary end...
PURPOSE: To identify prognostic factors and a model predictive for survival in patients with metastatic renal-cell carcinoma (RCC). PATIENTS AND METHODS: The relationship between pretreatment clinical features was studied 670 advanced RCC treated 24 Memorial Sloan-Kettering Cancer Center trials 1975 1996. Clinical were first examined univariately. A stepwise modeling approach based on Cox proportional hazards regression then used to form multivariate model. performance of the internally...
Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in high expression pro-angiogenic growth factors: vascular endothelial factor (VEGF) and platelet-derived (PDGF). SU11248 (sunitinib malate), a small molecule inhibitor with binding affinity for VEGF PDGF receptors, was tested clinical activity patients metastatic RCC.Patients RCC progression on first-line cytokine therapy were enrolled onto multicenter phase II trial....
PURPOSE: To define outcome data and prognostic criteria for patients with metastatic renal cell carcinoma (RCC) treated interferon-alfa as initial systemic therapy. The can be applied to design interpretation of clinical trials new agents treatment programs against this refractory malignancy. PATIENTS AND METHODS: Four hundred sixty-three advanced RCC administered interferon-α first-line therapy on six prospective were the subjects retrospective analysis. Three risk categories predicting...
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared that sunitinib is unclear.
The efficacy and safety of nivolumab plus cabozantinib as compared with those sunitinib in the treatment previously untreated advanced renal-cell carcinoma are not known.
Current treatment options for metastatic renal cell carcinoma (RCC) are limited and there is a need to identify novel effective therapies. Sunitinib malate an oral multitargeted tyrosine kinase inhibitor, which has shown activity in initial study of cytokine-refractory RCC patients.To confirm the antitumor efficacy sunitinib as second-line patients with clear-cell RCC, predominant type this malignancy.Open-label, single-arm, multicenter clinical trial. Patients were enrolled between February...
Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well MET and AXL, each of which has been implicated in the pathobiology metastatic renal-cell carcinoma or development resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated efficacy cabozantinib, compared with everolimus, patients had progressed after VEGFR-targeted therapy.We randomly assigned 658 receive cabozantinib at a...
Abstract BACKGROUND: A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor–tyrosine kinase inhibitors. Final results and of prognostic factors are reported. METHODS: Patients mRCC (N = 416) were randomized (2:1) to 10 mg/d (n 277) or 139) plus best supportive care. Progression‐free survival (PFS) safety assessed the end double‐blind treatment....
Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve survival in a subset of patients with clear renal carcinoma (ccRCC). To identify genomic alterations ccRCC that correlate response to anti-PD-1 monotherapy, we performed whole-exome sequencing metastatic from 35 patients. We found clinical benefit was associated loss-of-function mutations PBRM1 gene (P = 0.012), which encodes subunit PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling...
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Patients Methods clear-cell mRCC previously treated agents targeting vascular endothelial growth factor pathway were randomly assigned (blinded ratio 1:1:1) to 0.3, 2, or 10 mg/kg intravenously...